Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 4
Submit an article Journal homepage
252
Views
9
CrossRef citations to date
0
Altmetric
Systematic Review

Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies

Rachel Huelin United BioSource Corporation, 430 Bedford Street, Suite 300, Lexington, MA 02420, USA; United BioSource Corporation, 430 Bedford Street, Suite 300, Lexington, MA 02420, USA. [email protected]
,
Tiffany Pokora United BioSource Corporation, 430 Bedford Street, Suite 300, Lexington, MA 02420, USA; United BioSource Corporation, 430 Bedford Street, Suite 300, Lexington, MA 02420, USA
,
Talia S Foster United BioSource Corporation, 430 Bedford Street, Suite 300, Lexington, MA 02420, USA; United BioSource Corporation, 430 Bedford Street, Suite 300, Lexington, MA 02420, USA
&
Joaquin F Mould Pfizer, Inc., 235 East 42nd Street, New York, NY 10017, USA; Pfizer, Inc., 235 East 42nd Street, New York, NY 10017, USA
Pages 505-523 | Published online: 09 Jan 2014

References

  • National Collaborating Centre for Chronic Conditions. Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in Adults. Royal College of Physicians, London, UK (2009).
  • National Collaborating Centre for Chronic Conditions. Osteoarthritis: National Clinical Guideline for Care and Management in Adults. Royal College of Physicians, London, UK (2008).
  • Lawrence RC, Felson DT, Helmick CG et al.; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 58(1), 26–35 (2008).
  • Lawrence RC, Helmick CG, Arnett FC et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41(5), 778–799 (1998).
  • Altman RD. Early management of osteoarthritis. Am. J. Manag. Care 16(Suppl. Management), S41–S47 (2010).
  • Boonen A, Severens JL. The burden of illness of rheumatoid arthritis. Clin. Rheumatol. 30(Suppl. 1), S3–S8 (2011).
  • White AG, Birnbaum HG, Janagap C, Buteau S, Schein J. Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States. J. Occup. Environ. Med. 50(9), 998–1005 (2008).
  • Sarzi-Puttini P, Cimmino MA, Scarpa R et al. Osteoarthritis: an overview of the disease and its treatment strategies. Semin. Arthritis Rheum. 35(Suppl. 1), 1–10 (2005).
  • Schnitzer TJ, Hochberg MC. COX-2-selective inhibitors in the treatment of arthritis. Cleve. Clin. J. Med. 69(Suppl. 1), SI20–SI30 (2002).
  • White WB, West CR, Borer JS et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am. J. Cardiol. 99(1), 91–98 (2007).
  • Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 376(9736), 173–179 (2010).
  • Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res. Ther. 7(3), R644–R665 (2005).
  • Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284(10), 1247–1255 (2000).
  • Chung SJ, Kwon YJ, Park HJ, Ko SK, Park MC. Cost–effectiveness of celecoxib, nonselective NSAID and NSAID with proton-pump inhibitor in patients with rheumatoid arthritis in Korea. Ann. Rheum. Dis. 69(Suppl. 3), 684 (2010).
  • Contreras-Hernández I, Mould-Quevedo JF, Torres-González R et al. Cost–effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors. Cost Eff. Resour. Alloc. 6, 21 (2008).
  • Lee KK, You JH, Ho JT et al. Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease. Aliment. Pharmacol. Ther. 18(2), 217–222 (2003).
  • Yen ZS, Lai MS, Wang CT et al. Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan. J. Rheumatol. 31(9), 1797–1803 (2004).
  • Yilmaz H, Gurel S, Keskinaslan A, Ozdemir O. The comparison of alternatives in osteoarthritis treatment with cost-minimization analysis. Turkiye Fiziksel. Tip. Ve. Rehabilitasyon Dergisi. 50(2), 4–10 (2004).
  • You JH, Lee KK, Chan TY, Lau WH, Chan FK. Arthritis treatment in Hong Kong – cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. Aliment. Pharmacol. Ther. 16(12), 2089–2096 (2002).
  • El-Serag HB, Graham DY, Richardson P, Inadomi JM. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost–effectiveness analysis. Arch. Intern. Med. 162(18), 2105–2110 (2002).
  • Kamath CC, Kremers HM, Vanness DJ, O’Fallon WM, Cabanela RL, Gabriel SE. The cost–effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health 6(2), 144–157 (2003).
  • Loyd M, Rublee D, Jacobs P. An economic model of long-term use of celecoxib in patients with osteoarthritis. BMC Gastroenterol. 7, 25 (2007).
  • Schaefer M, DeLattre M, Gao X, Stephens J, Botteman M, Morreale A. Assessing the cost–effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. Curr. Med. Res. Opin. 21(1), 47–60 (2005).
  • Maetzel A. Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis. Canadian Coordinating Office for Health Technology Assessment 6, 1–15 (2002).
  • Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum. 49(3), 283–292 (2003).
  • Bessette L, Risebrough N, Mittmann N, Roussy JP, Ho J, Zlateva G. Cost–utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective. J. Med. Econ. 12(3), 246–258 (2009).
  • Zabinski R, Burke T, Johnson J et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 19(Suppl. 1), 49–58 (2001).
  • Moreno A, Vargas E, Soto J, Rejas J. Cost–effectiveness analysis of the use of celecoxib for the treatment of osteoarthritis. Gac. Sanit. 17(1), 27–36 (2003).
  • Rubio-Terres C, Moller PI, Campeny ET, Verges MJ. Pharmacoeconomic analysis of arthrosis treatment with chondroitin sulfate in comparison to NSAIs. Atencion Farmaceutica 6(1), 15–27 (2004).
  • Vargas E, Laredo L, Soto J, Rejas J. Economic evaluation of celecoxib in the treatment of arthrosis. Atencion Farmaceutica 4(2), 72–82 (2002).
  • Chen YF, Jobanputra P, Barton P et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol. Assess. 12(11), 1–278, iii (2008).
  • Holmstrom S, Svedbom A, Borgstrom F, Miltenburger C. Estimation of costs related to adverse events in NSAID treatment of osteoarthritis – a comparison between celecoxib and ibuprofen using a validated model. Presented at: International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting. Orlando, FL, USA , 16–20 May 2009.
  • Lucioni C, Chiroli S, Roggeri D, Annoni G. Cost-analysis of a 6-week cycle of therapy with celecoxib vs conventional NSAIDs in ostheoarthritis in Italy. PharmacoEcon. Ital. Res. Art. 5(1), 23–34 (2003).
  • Dahlberg LE, Holme I, Høye K, Ringertz B. A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis. Scand. J. Rheumatol. 38(2), 133–143 (2009).
  • Chancellor JV, Hunsche E, de Cruz E, Sarasin FP. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Pharmacoeconomics 19(Suppl. 1), 59–75 (2001).
  • Al MJ, Maniadakis N, Grijseels EW, Janssen M. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in The Netherlands. Value Health 11(4), 589–599 (2008).
  • Inotai A, Mészáros A. Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis. Int. J. Technol. Assess. Health Care 25(2), 190–195 (2009).
  • García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol. 52(20), 1628–1636 (2008).
  • Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342, c7086 (2011).
  • Soloman N. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071–1080 (2005).
  • Arber N, Eagle CJ, Spicak J et al.; PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355(9), 885–895 (2006).
  • Bombardier C. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 21, 1520–1528 (2000).
  • Brixner DI, Joish VN, Odera GM, Avey SG, Hanson DM, Cannon HE. Effects of benefit design change across 5 disease states. Am. J. Manag. Care 13(6 Pt 2), 370–376 (2007).
  • Moride Y, Ducruet T, Rochon S, Lavoie F. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. Rheumatology (Oxford) 42(Suppl. 3), iii17–iii22 (2003).
  • Shi W, Wang YM, Li LS et al. Safety and efficacy of oral nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis: a six-month randomised study. Clin. Drug Investig. 24(2), 89–101 (2004).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.